Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
05 October 2023 - 3:14AM
Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage
precision oncology company developing therapies that target
families of oncogenic mutations in patients with genetically
defined cancers, today announced forthcoming presentations during
the AACR-NCI-EORTC International Conference on Molecular Targets
and Cancer Therapeutics in Boston, October 11-15, 2023. The three
poster presentations include initial dose escalation data from the
Company’s Phase 1 clinical trial of BDTX-1535 in non-small cell
lung cancer (NSCLC), the study design of this ongoing Phase 1
clinical trial, and preclinical data for BDTX-4933.
Details for the presentations are as
follows:
Title: Phase 1 Study of
BDTX-1535, an Oral 4th Generation EGFR Inhibitor, in Patients with
NSCLC andGBM: Preliminary Dose Escalation
ResultsSpeaker: Helena Yu, M.D., Associate
Attending Physician, Memorial Sloan Kettering Cancer Center
Time: Poster Session C, Saturday, October 14,
12:30 pm-4:00 pmLocation/Poster #: Level 2,
Exhibit Hall D, #C022
Title: A Phase 1 Study to
Assess BDTX-1535, an Oral 4th Generation EGFR Inhibitor, in
Patients with NSCLC and GBM Speaker: Helena Yu,
M.D., Associate Attending Physician, Memorial Sloan Kettering
Cancer CenterTime: Poster Session C, Saturday,
October 14, 12:30 pm-4:00 pmLocation/Poster #:
Level 2, Exhibit Hall D, #C036
Title: Preclinical Efficacy of
BDTX-4933, a Brain-penetrant, Orthosteric RAF Inhibitor, Targeting
Oncogenic RAF Conformation Shared by Groups of BRAF and Upstream
Driver MutationsSpeaker: Elizabeth Buck, Ph.D.,
Chief Scientific Officer, Black Diamond Therapeutics
Time: Poster Session A, Thursday, October 12,
12:30 pm-4:00 pmLocation/Poster #: Level 2,
Exhibit Hall D, #A090
About BDTX-1535BDTX-1535 is a
brain-penetrant and potent MasterKey inhibitor of oncogenic
mutations of epidermal growth factor receptor (EGFR) in non-small
cell lung cancer (NSCLC), including families of intrinsic driver
mutations and acquired resistance C797S mutation that result
post-treatment with osimertinib. While current treatments for NSCLC
target singular mutations, BDTX-1535 has the potential to address
approximately 50 different mutations across a diverse group of
patients in multiple lines of therapy. BDTX-1535 also has the
potential to treat patients with glioblastoma multiforme (GBM)
expressing EGFR alterations. The ongoing BDTX-1535 Phase 1 clinical
trial is currently in dose expansion for NSCLC and dose escalation
for GBM.
About Black Diamond
TherapeuticsBlack Diamond Therapeutics is a clinical-stage
precision oncology medicine company focused on the development of
therapies that target families of oncogenic mutations in clinically
validated targets. Black Diamond leverages a deep understanding of
cancer genetics and onco-protein structure and function, to
discover and develop innovative therapies. The Company’s MasterKey
therapies are designed to overcome resistance, minimize on-target,
wild-type mediated toxicities, and be brain-penetrant to address
significant unmet medical needs of patients with genetically
defined cancers. The Company is advancing a robust pipeline with
lead clinical-stage program BDTX-1535, targeting oncogenic
mutations in both EGFR mutant-positive NSCLC and in GBM, and
BDTX-4933, a program targeting RAF mutations in solid tumors. For
more information, please visit
www.blackdiamondtherapeutics.com.
Forward-Looking
StatementsStatements contained in this press release
regarding matters that are not historical facts are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Because such statements
are subject to risks and uncertainties, actual results may differ
materially from those expressed or implied by such forward-looking
statements. Such statements include, but are not limited to,
statements regarding: the potential of BDTX-1535 to address
multiple mutations across a diverse group of NSCLC patients in
multiple lines of therapy and to treat patients with GBM. Any
forward-looking statements in this statement are based on
management’s current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in
or implied by such forward-looking statements. Risks that
contribute to the uncertain nature of the forward-looking
statements include those risks and uncertainties set forth in its
Annual Report on Form 10-K for the year ended December 31, 2022,
filed with the United States Securities and Exchange Commission and
in its subsequent filings filed with the United States Securities
and Exchange Commission. All forward-looking statements contained
in this press release speak only as of the date on which they were
made. The Company undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
Contacts
For Investors:Mario Corso, Head of Investor
Relations, Black Diamond Therapeuticsmcorso@bdtx.com
Julie Seidel, Stern Investor
Relationsinvestors@bdtx.com
For Media:Joan Bosisio, Verge Scientific
Communicationsmedia@bdtx.com
Black Diamond Therapeutics (NASDAQ:BDTX)
Historical Stock Chart
From May 2024 to Jun 2024
Black Diamond Therapeutics (NASDAQ:BDTX)
Historical Stock Chart
From Jun 2023 to Jun 2024